collected for all patients. Cost-minimization analysis was performed by using the drug acquisition cost for meropenem. Demographics, sources of infection, distributions of organisms, and Charlson Comorbidity Index scores were similar between patients in the traditionally and alternatively dosed groups. Concomitant therapy, duration of therapy, success rates, lengths of stay, and in-hospital mortality rates were also similar between groups. Median time to the resolution of symptoms was 3 days for traditional dosing and 1.5 days for alternative dosing (p<0.0001). A logistic regression model including the dosing strategy showed that only polymicrobial infections and sepsis were associated with increased failure rates. The median cost for antibiotics was $439.05/patient for traditional dosing and $234.08/patient for alternative dosing (p<0.0001). Conclusion. An alternative dosing regimen for meropenem with a lower total daily dose yielded patient outcomes, including success rates and duration of therapy, equivalent to those of the traditional dosing regimen. Alternative dosing decreased total drug exposure, costs for antibiotics, and time to the resolution of infections.
potentially limit the cost-prohibitive nature of some agents.
Pharmacodynamic parameters to optimize killing activity for various antibiotics have been established. As these pertain to carbapenems, meropenem and imipenem-cilastatin have demonstrated time-dependent killing activity; the primary parameter predicting effectiveness was the time above the minimum inhibitory concentration (MIC). [1] [2] [3] Substantially increasing drug concentrations above the MIC did not increase the rate of bactericidal activity. Animal models have shown that concentrations of meropenem should remain above the MIC for approximately 20% or 40% of the dosing interval for the drug to have a bacteriostatic or bactericidal effect, respectively. 3 Mathematic modeling has been applied to predict the attainment of pharmacodynamic targets by using various dosing regimens. Monte Carlo simulations have proven to be particularly useful. Such simulations can be designed to mimic interpatient variability and to assess multiple antibiotic dosing regimens to predict drug exposures and time above the MIC. Investigators used estimates of pharmacokinetic parameters from 5000 healthy volunteers to simulate exposure at the susceptibility breakpoint of meropenem (4 µg/ml) for gramnegative organisms and Staphylococcus aureus. 4 Regimens compared included 500 mg infused over 30 minutes every 6 hours and 1 g over 30 minutes every 8 hours. The mean percentage time above the MIC was 45.77% (95% confidence interval 40.06-50.69%) for 1 g every 8 hours and 43.91% (95% confidence interval 36.77-51.46%) for 500 mg every 6 hours. In addition, costminimization analysis showed a predicted decrease in daily costs of $38.64 when 500 mg every 6 hours was used instead of 1 g every 8 hours. Results of this simulation provided the foundation for adopting alternative dosing of meropenem into clinical practice.
On the basis of these mathematic models, researchers evaluated the clinical and economic implications of using meropenem 500 mg over 30 minutes every 6 or 8 hours versus 1 g over 30 minutes every 8 or 12 hours. 5 In a small observational study, they demonstrated that the smaller dose given more frequently achieved microbiologic and clinical success rates equivalent to those of the higher dose given less frequently. Of 60 patients included in the analysis, 78% of those taking 500 mg every 6 hours and 82% of those taking 1 g every 8 hours had clinical success (p=0.862). Thirty-eight patients were included in the microbiologic analysis. Microbiologic success was achieved in 63% of patients given 500 mg every 6 hours and in 79% of patients given 1 g every 8 hours (p=0.334). Equivalent outcomes were attained, and drug acquisition costs for the course of treatment were 41% lower for the 500-mg regimen compared with the 1-g regimen ($576 vs $982, p=0.009). The small sample size may have been a study limitation, but the results suggested that clinical outcomes were similar between the two dosing regimens and that the daily acquisition costs associated with antibiotic therapy were reduced with the 500-mg regimen.
At the Medical Center of Plano, Texas, meropenem has been on formulary since 2002 and traditionally dosed at 1 g every 8 or 12 hours. Given the published outcomes and cost data, we implemented a pharmacist-initiated autosubstitution protocol to convert dosages of meropenem to 500 mg every 6 or 8 hours. The staff at our institution believed that a decreased total daily dose of meropenem could provide equivalent drug exposure. If true, the reduction in dose would allow us to realize clinical success while decreasing drug acquisition cost.
The goal of this study was to describe drug use and outcomes for patients treated with alternative dosing of meropenem compared with a historical control group treated with the United States Food and Drug Administration-approved regimen. Our primary objective was to determine if an alternative dosing strategy provides clinical outcomes similar to those of the traditional regimen while allowing our institution to reduce drug acquisition costs.
Methods

Study Design
This was a retrospective cohort analysis designed to compare the epidemiology, treatment, and outcome results of patients treated with an alternative dosing regimen for meropenem implemented on October 1, 2004, with those of historical controls treated with traditional dosing. A cohort study with cost-minimization analysis was also performed.
The study was performed at the Medical Center of Plano, a 427-bed, privately owned community hospital in a suburb of Dallas, Texas. The pharmacy staff developed the protocol, and the pharmacy and therapeutics committee approved it. Approval was also obtained from the hospital' s institutional review board. Because this was a retrospective review, patient consent was not required.
The pharmacy staff underwent extensive education before the change in dosing was implemented. Pharmacists performed the dose conversions when physicians wrote the orders.
Creatinine clearances for all patients were calculated by using the Cockcroft-Gault equation. 6 
Study Population
Inclusion Criteria
Patients were included as the historical controls if they received meropenem 1 g over 30 minutes every 8 or 12 hours between January 1 and September 30, 2004 (traditional dosing group). Patients with a creatinine clearance greater than or equal to 50 ml/minute received meropenem 1 g over 30 minutes every 8 hours, and patients with a creatinine clearance of 25-49 ml/minute received 1 g over 30 minutes every 12 hours.
Patients were included in the alternative dosing group if they received meropenem 500 mg over 30 minutes every 6 or 8 hours between October 1, 2004, and September 30, 2005 . Patients with a creatinine clearance greater than or equal to 50 ml/minute were given meropenem 500 mg over 30 minutes every 6 hours. Patients with a creatinine clearance of 25-49 ml/minute were given 500 mg over 30 minutes every 8 hours.
Exclusion Criteria
Exclusion criteria were age younger than 18 years, pregnancy, neutropenia (absolute neutrophil count < 1000 cells/mm 3 ), suspected or documented meningitis, cystic fibrosis, or a creatinine clearance of less than 25 ml/minute. Patients who had changes in renal function that led to a creatinine clearance of less than 25 ml/minute were excluded from the clinical analysis. Patients with prescribed meropenem dosages greater than 1 g every 8 hours (e.g., those with febrile neutropenia, suspected or documented meningitis, or cystic fibrosis) or dosages less than 1 g every 12 hours were also excluded. Patients in the alternative dosing group were allowed one 1-g dose of meropenem; if they received more than one 1-g dose, they were excluded. Patients who were converted from 500 mg over 30 minutes every 6 or 8 hours to traditional dosing were also excluded. Furthermore, patients who received a dosage that was inappropriate for their renal function for longer than 1 day were excluded. Patients who received meropenem and who were found to have an organism resistant to meropenem when they began therapy were also excluded.
Data Collection
Patients' demographic and clinical data, such as age, weight, sex, serum creatinine concentration, and comorbidities, were collected. Charlson Comorbidity Index scores were calculated by using preexisting comorbidities, including any history of myocardial infarction, liver disease, chronic obstructive pulmonary disease, chronic heart failure, peripheral vascular disease, cerebrovascular disease, human immunodeficiency virus infection, leukemia, lymphoma, metastatic solid tumors, any tumor in the last 5 years, dementia, connective tissue disease, peptic ulcer disease, hemiplegia, and renal disease. 7 Microbiologic data were the genus, species, and MIC breakpoints of all organisms isolated by using the MicroScan system (Deerfield, IL). Polymicrobial infections were defined as the presence of two gram-negative organisms, a gram-positive and a gram-negative organism, or a gram-negative organism and an anaerobe. Sepsis was defined as a condition meeting the Surviving Sepsis criteria 8 or a physician' s clinical diagnosis. Concomitant therapy with aminoglycosides, fluoroquinolones, vancomycin, linezolid, and metronidazole was examined. Oral vancomycin and antifungals were not included in the analysis of concomitant therapy.
Data specific to meropenem use consisted of the dose, dosing interval, and duration of therapy.
Outcomes Assessment
Patients were included in the clinical analysis if they received meropenem therapy for at least 3 full days. Outcomes evaluated were meropenemrelated length of stay, in-hospital mortality, time to defervescence, and success or failure of therapy. Meropenem-related length of stay was defined as the number of days from the start of meropenem therapy to the day of discharge. Time to defervescence was defined as time to normalization of leukocytes (white blood cell count 4-10.8 x 10 3 /mm 3 ) and a body temperature below 100.5°F. Clinical outcome was evaluated as treatment success or failure. Clinical success was defined as complete or partial resolution of leukocytosis, temperature, and clinical signs and symptoms of infection. For a complete response, all factors had to be resolved. For a partial response, all factors had to be stable or improving. Clinical failure was the persistence of signs and symptoms of infection, intolerance of meropenem, or death due to infection. If a patient developed a pathogen resistant to meropenem while receiving meropenem therapy, this event was counted as a treatment failure. The addition of an agent for gram-positive coverage, such as vancomycin, was not considered a clinical failure.
Patients who never had leukocytosis or who never had an elevated body temperature were excluded from the analysis of clinical outcome. When a situation was unclear, two investigators independently determined its success or failure. A consensus was reached between the two investigators if their initial assessments differed.
Economic Analysis
Patients were included in the economic analysis if they received meropenem therapy for at least 1 full day. Cost-minimization analysis was performed, and differences in drug acquisition costs between traditional and alternative dosing were investigated. Data included in the economic analysis were the dosage of meropenem, the dosing interval of meropenem administration, the number of intravenous doses of meropenem administered, the duration of meropenem therapy, and the drug acquisition cost for meropenem.
Statistical Analysis
Descriptive statistics were used to evaluate epidemiologic, microbiologic, and baseline demographic and clinical data. Patients' characteristics and outcomes were compared between the traditional and alternative dosing groups. We also evaluated the effect of various independent risk factors, including age, sex, race, Charlson Comorbidity Index scores, and meropenem dosing group, on clinical outcomes.
Initial analyses were conducted with 2-tailed univariate tests of association: a
Comparisons were considered statistically significant when the p value was 0.05 or less. Statistical software (SPSS version 11.0; SPSS, Chicago, IL), was used for all calculations.
Results
Clinically evaluable groups consisted of 100 patients who received traditional dosing of meropenem and 192 patients who received alternative dosing. The conversion to the alternative dosing strategy was successful, with a 99% conversion rate. Of the traditionally dosed patients, 77% received meropenem 1 g every 8 hours, and 23% received 1 g every 12 hours due to renal insufficiency. Among the alternatively dosed patients, 67.7% received 500 mg every 6 hours and 32.3% received 500 mg every 8 hours due to renal insufficiency. We observed no significant differences in patient demographics, Charlson Comorbidity Index scores, infection sources, and lengths of stay before meropenem started (Table 1 ) or in the distribution of organisms between the groups (Table 2) .
Isolates included all pathogens isolated and not specifically the isolates treated with meropenem. No significant differences were observed in prescribed concomitant therapies between the cohorts (Table 3 ). Likewise, overall success rates did not significantly differ for monotherapy versus combination therapy (95.4% vs 89%, p=0.286).
Meropenem-related lengths of stay, in-hospital mortality, and duration of therapy were similar between groups (Table 4) .
For 87 traditionally dosed patients, the median time to resolution of infection was 3 days (range 1-22 days) compared with 1.5 days (range 1-10 days) for 156 alternatively dosed patients (p<0.0001). Success rates in traditionally and alternatively dosed patients were not statistically significantly different (90.9% and 92.1%, respectively, p=0.72).
Univariate analysis of outcomes showed that polymicrobial infections, diabetes mellitus, and sepsis were associated with an increased failure rate (Table 5 ). After we controlled for these factors, for Charlson Comorbidity Index scores, and for dosing regimen used in the multivariate regression, only sepsis or polymicrobial infection was predictive of clinical failure (Table 6 ). Success and failure rates were not examined according to specific pathogens because of an inadequate number of individual isolates available in each group.
Cost-minimization analysis revealed a significant decrease in drug acquisition costs when the alternative dosing strategy was used. Median antibiotic cost/patient for the duration of meropenem therapy was $439.05 for traditional dosing and $234.08 for alternative dosing (p<0.0001). Therefore, a reduction of $204.97/ patient, or nearly 50%, for meropenem was realized during the study. For the 1-year study in which 192 patients were treated with alternative dosing, this reduction amounted to almost $40,000 in antibiotic cost savings to the institution. Defined as number of days from the start of meropenem therapy to the day of discharge.
Discussion
Formulary decision-makers are frequently challenged with decisions about antibiotics, including those regarding the best application of guidelines and optimal doses. Alternative dosing is often attractive, but clinical data supporting strategies other than those used in clinical trials are limited. Clinical outcomes studies of antimicrobial therapy primarily focus on applying pharmacodynamic principles to determine the dose needed to maximize pharmacokinetic and pharmacodynamic parameters. Few investigators have evaluated the clinical effect of alternative dosing regimens. At the Medical Center of Plano, we were intrigued by the possibility of administering a decreased total daily dose of meropenem while attaining similar clinical successes and realizing economic benefits. The change to alternative dosing was implemented hospitalwide, and it was not limited by the organism or hospital unit. The conversion was extremely successful, and only 1% of patients were not converted or were converted back to the traditional dosing. Alternative dosing resulted in clinical success rates similar to those of traditional dosing and shortened the time for infections to resolve.
Previous investigators suggested that patients who received small doses more frequently than higher doses less frequently had similar clinical outcomes at a reduced cost. 5 Our study corroborated these results by demonstrating a 92.1% treatment success rate for alternatively dosed patients compared with 90.9% for traditionally dosed patients. Although the meropenem-related length of stay and in-hospital mortality rates were higher in the alternative dosing group, the difference between groups was not statistically significant. Of note, patients were not stratified by risk and comorbidities, and concomitant disease states were not taken into account in the univariate outcome measures. Therefore, these measures could not be attributed to the alternative dosing of meropenem alone. Like the previous investigators, 5 we realized a significant reduction in drug acquisition costs, which were reduced by 50% at our institution. Our trial design and results were similar to theirs, 5 but our sample size of patients was larger, and our protocol was implemented hospitalwide. We demonstrated that it was possible to implement an alternative dosing regimen at a community hospital, and our results suggest both clinical and economic success.
Our study has inherent limitations. Retrospective evaluation of clinical success and failure is difficult. To help control for this factor, we considered several objective patient parameters, including reductions in body temperature and white blood cell counts in addition to clinical responses when we determined treatment success and failures. Also, the fact that only two investigators reached a consensus was a limitation. Having a third, independent investigator to review clinical successes or failures would have been an improvement.
For almost 50% of patients, no bacteria were identified on cultures. Therefore, microbial eradication was eliminated as an outcome measure. In addition, empiric use was allowed. Therefore, most patients who started empiric treatment with meropenem continued with the regimen after their culture results were available. All patients were evaluated, including those with organisms not covered by meropenem. Much of the use of meropenem was empiric; therefore, we did not examine the time to appropriate therapy and previous antibiotic therapy. Because patients with concurrent illness or infection were not excluded, the contribution of their concurrent condition to the clinical success or failure of meropenem therapy could not be determined. Oral vancomycin for Clostridium difficile and antifungals were not evaluated as concomitant therapy; this was an inherent limitation. Although combination therapy was allowed, it did not affect overall success rates, which were similar between monotherapy and combination therapy.
Another limitation was that we evaluated only drug acquisition costs when we determined the pharmacoeconomic effect of implementing the protocol. However, additional factors, such as drug preparation and administration costs, also contribute to the overall costs of treating a patient. The costs of materials, such as tubing and an extra infusion bag, are minimal. Additional costs such as those related to nursing administration time and labor are generally considered fixed costs that would not have been affected.
Conclusion
The alternative dosing regimen examined in this study was a practical and effective way to use meropenem. Because almost 50% of our patients received empiric therapy, this study was not conducted as an efficacy trial but as an evaluation of real-world experience with alternative dosing of meropenem. The meropenem-related length of therapy, in-hospital mortality rate, duration of therapy, and success rate of alternative dosing were at least equivalent to those observed with traditional dosing. Time to defervescence reduced with alternative dosing. Alternative dosing did not contribute to failures in therapy. Failure rates were attributed to only sepsis and polymicrobial infections. In addition, drug acquisition costs were reduced by almost 50%. Therefore, alternative dosing may be an intriguing way to use meropenem in a clinical and cost-effective manner. These data contribute to the current body of literature about this issue. However, further prospective randomized trials are still necessary.
